# Study of 177Lu-LNC1004 Injection in FAP-positive Radioiodine-refractory Differentiated Thyroid Cancer

> **NCT06898437** · EARLY_PHASE1 · RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Radioiodine Refractory Differentiated Thyroid Cancer

## Interventions

- **DRUG:** 177Lu-LNC1004 Injection

## Key facts

- **NCT ID:** NCT06898437
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-24
- **Primary completion:** 2026-03-23
- **Final completion:** 2027-03-23
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06898437

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06898437, "Study of 177Lu-LNC1004 Injection in FAP-positive Radioiodine-refractory Differentiated Thyroid Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06898437. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*